-
We are excited to announce new enhancements in the platform between July and September 2023 Over the past three months, we’ve added data from over 780K publications and 1.2M products . Other notable updates include: Access thousands of n...
-
There are a few ways to get in touch with us! Feel free to reach out to our Scientific Support team through one of these methods. Someone will be in touch within 1 business day! In-app Chat Email Request Form Click at the...
-
ASCEND is a web-based platform that is designed to work best on a modern web browser on a desktop computer or laptop . Please check out this article to read more about supported browsers. ...
-
We are excited to announce new enhancements in the platform between January and March 2024
Over the past three months, we’ve added data from over 2.1M publications, 17M experimental use cases, and 173K reagents and model systems. ...
-
我们已为平台添加了新功能，并引入三个新的应用程序：Navigator、Architect 和 Defender。我们的平台现在叫做 BenchSci 的 ASCEND！ 什么是 ASCEND 平台？ ASCEND 平台由 4 个应用程序组成，包括 Selector（之前的 Reagent Selection）。这套应用程序可使用户发现生物连接、揭示相关实验证据，并在实验中尽早发现安全性和有效性风险，从而更快地推进最有前景的项目。 Selector Navigat...
-
プラットフォームに新しい機能を追加し、次の3つの新しいアプリケーションを導入しました：ナビゲーター、アーキテクト、ディフェダー。当社のプラットフォームは「ASCEND by BenchSci」と呼ばれています！ ASCENDプラットフォームとは何ですか？ ASCENDプラットフォームは、セレクター（以前は「試薬選択」）を含む4つのアプリケーションで構成されています。この一連のアプリケーションにより、ユーザーは生物学的なつながりを発見し、条件に応じた実験的証拠を浮き彫りにし、実験における...
-
We are excited to announce new enhancements in the platform between April and June 2024
Over the past three months, we have added data from over 811K publications , 1.7M experimental use cases , and 494K reagents . Other notable ...
-
Whether it's ASCEND's quarterly updates or new feature releases, stay informed through the following channels to make the most of its capabilities for your research needs. 1. Visit the Knowledge Center The ASCEND Knowledge Center is ri...
-
A look back at some exciting features that we built in 2024 to empower scientists to design more successful experiments
We expanded our data coverage
In 2024 we focused on increasing our coverage of closed access journal art...